empty
 
 
sp
Búsqueda
Soporte
Apertura instantánea de la cuenta
Plataforma comercial
Depositar/Retirar
Búsqueda
Para Principiantes Para Operadores Para Socios Haga una pausa Sobre InstaSpot
sp
#ACB Voltar para a lista de instrumentos #AMGN

Conversor de moeda

Alnylam Pharmaceuticals Inc.
303.7 USD
24 Apr 2026 21:59
Alterar preço (% chg)
$0
(0%)
Fechamento anterior
Fechamento anterior

Preço de fechamento, dia anterior.
$310.46
Abrir
Abrir

Preço de abertura.
$309.59
Alta do dia
Alta do dia

O preço mais alto durante o último dia de negociação.
$311.92
Baixa do dia
Baixa do dia

O preço mais baixo durante o último dia de negociação
$302.24
Alta 52-semanas
Alta 52-semanas

Alta no intervalo De preço das últimas 52 semanas
$339.06
Baixa 52-semanas
Baixa 52-semanas

Baixa no intervalo De preço das últimas 52 semanas
$302.24
Download do arquivo
Comprar
303.7
Vender
303.7
Abra el gráfico en pantalla completa
Comprar
303.7
Vender
303.7
Download do arquivo
Abra el gráfico en pantalla completa

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

¿No puede hablar ahora mismo?
Ingrese su pregunta en el chat.